- Direct factor Xa inhibitor rivaroxaban2009 | Faculty of Medicine in Hradec Králové
- Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study2008 | First Faculty of Medicine
- Rivaroxaban - a newly marketed antithrombotic agent2009 | First Faculty of Medicine
- Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study +12008 | Faculty of Medicine in Hradec Králové
- Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study2008 | Second Faculty of Medicine
- Anticoagulation 20132013 | Faculty of Medicine in Hradec Králové
- Major Bleeding in Patients With Atrial Fibrillation Receiving Apixaban or Warfarin2014 | Publication without faculty affiliation
- Apixabans2011 | First Faculty of Medicine, Third Faculty of Medicine
- Randomized, Double-Blind, Dose-Ranging Sudy of Otamixaban, a Novel, Parenteral, Short-Acting Direct Factor Xa Inhibitor, in Percutaneous Coronary Intervention. The SEPIA-PCI Trial2007 | First Faculty of Medicine
- Randomized, Double-Blind, Dose-Ranging Sudy of Otamixaban, a Novel, Parenteral, Short-Acting Direct Factor Xa Inhibitor, in Percutaneous Coronary Intervention. The SEPIA-PCI Trial2007 | Faculty of Physical Education and Sport
- Endovascular Stroke Treatment and Risk of Intracranial Hemorrhage in Anticoagulated Patients2020 | Faculty of Medicine in Hradec Králové
- Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial2009 | Third Faculty of Medicine
- Rivaroxaban - Metabolism, Pharmacologic Properties and Drug Interactions2017 | First Faculty of Medicine
- Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome2011 | Publication without faculty affiliation
- Rivaroxaban versus Enoxaparin for thromboprophylaxis after total knee arthroplasty2008 | Central Library of Charles University
- Rivaroxaban versus Enoxaparin for thromboprophylaxis after total knee arthroplasty2008 | Faculty of Medicine in Pilsen
- Rivaroxaban versus Enoxaparin for thromboprophylaxis after total knee arthroplasty2008 | First Faculty of Medicine, Faculty of Medicine in Pilsen
- Commentary on Aristotle study (Apixaban compared with warfarin in patients with atrial fibrillation)2011 | First Faculty of Medicine
- Pharmacological prevention of thrombembolic disease - part 22011 | Central Library of Charles University, First Faculty of Medicine
- Pharmacological prevention of thrombembolic disease - part 12011 | Central Library of Charles University, First Faculty of Medicine
- What we expect from anticoagulant therapy in 20142014 | Publication without faculty affiliation
- Low molecular weight heparins - their significance in current practice2011 | Central Library of Charles University, Third Faculty of Medicine
- Consensus recommendations for the prophylaxis of venous thrombosis after total joint replacement (TEP) of the hip or kneePublication without faculty affiliation
- Anticoagulation therapy in 20152015 | First Faculty of Medicine
- Anticoagulation therapy in 20152016 | Publication without faculty affiliation
- New antithrombotics in the prevention of venous thromboembolia and new anti-platelet drugs2011 | Faculty of Medicine in Hradec Králové
- Apixaban in patients with atrial fibrillation and impaired renal function - subanalysis of ARISTOTLE study2013 | Publication without faculty affiliation
- Apixaban has been available for the treatment of venous thromboembolic disease for more than two years +12017 | First Faculty of Medicine, Third Faculty of Medicine